나노의학 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 나노분자 유형별, 나노입자 유형별, 질환 적응증별 용도별, 지역별, 경쟁별(2020-2030년)

The Global Nanomedicine Market, valued at USD 174.10 Billion in 2024, is projected to experience a CAGR of 9.10% to reach USD 293.59 Billion by 2030. Nanomedicine represents the application of nanotechnology in healthcare, utilizing materials and devices typically ranging from 1 to 100 nanometers for the diagnosis, treatment, and prevention of diseases. This approach leverages the unique properties of nanoscale structures to enhance drug solubility, stability, targeted delivery, and bioavailability.

Key Market Drivers

The global nanomedicine market experiences significant impetus from two primary factors: ongoing advancements in nanotechnology innovation and the increasing prevalence of chronic diseases. Technological progress consistently yields novel tools and materials, enabling sophisticated diagnostic and therapeutic applications within healthcare. For instance, according to the National Institutes of Health, in July 2023, the Notice of Funding Opportunity for "Innovative Research in Cancer Nanotechnology (IRCN) R01 Grant" was published, with application deadlines including November 2023 and May 2024, demonstrating sustained investment in fundamental research in this specialized area. Concurrently, the rising global burden of chronic diseases intensifies the demand for more effective medical interventions.

Key Market Challenges

A significant challenge impeding the expansion of the Global Nanomedicine Market is the substantial cost associated with the development and complex manufacturing processes of these specialized products. The intricate nature of nanotechnology-based interventions necessitates considerable upfront investment in research, highly specialized equipment, advanced infrastructure, and a workforce with unique expertise. These requirements often lead to protracted development timelines and increased operational expenditures throughout the product lifecycle, from initial synthesis to large-scale production.

Key Market Trends

The increasing shift towards personalized nanomedicine stands as a significant factor shaping the global nanomedicine market. This trend emphasizes tailoring medical treatments to individual patient characteristics, leveraging nanotechnology's ability to deliver drugs precisely and enhance diagnostic accuracy. Personalized nanomedicine offers the potential for improved therapeutic efficacy and reduced adverse effects by targeting specific cells or tissues. According to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U. S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a notable increase from the 12 approved in 2022. This demonstrates a growing regulatory recognition and market adoption of personalized approaches, which nanomedicine profoundly supports.

Key Market Players

• Pfizer Inc.
• Johnson & Johnson Innovative Medicine
• Sanofi S.A.
• Amgen Inc.
• Moderna, Inc.
• Novo Nordisk A/S
• Genentech, Inc.
• Celgene Corporation
• Vifor Pharma Group
• Teva Pharmaceutical Industries Ltd.

Report Scope:

In this report, the Global Nanomedicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nanomedicine Market, By Nanomolecule Type:

• Nanoparticles
• Nanoshells
• Nanodevices
• Nanotubes

Nanomedicine Market, By Nanoparticles Type:

• Polymer-based
• Lipid-based
• Nanocrystals
• Inorganic
• Others

Nanomedicine Market, By Application:

• Drug Delivery
• Vaccines
• Diagnostic Imaging
• Regenerative Medicine
• Others

Nanomedicine Market, By Disease Indication:

• Oncological Diseases
• Infectious Diseases
• Orthopedic Disorders
• Cardiovascular Diseases
• Others

Nanomedicine Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Nanomedicine Market.

Available Customizations:

Global Nanomedicine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Nanomedicine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Nanomolecule Type (Nanoparticles, Nanoshells, Nanodevices, Nanotubes)
  • 5.2.2. By Nanoparticles Type (Polymer-based, Lipid-based, Nanocrystals, Inorganic, Others)
  • 5.2.3. By Application (Drug Delivery, Vaccines, Diagnostic Imaging, Regenerative Medicine, Others)
  • 5.2.4. By Disease Indication (Oncological Diseases, Infectious Diseases, Orthopedic Disorders, Cardiovascular Diseases, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Nanomedicine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Nanomolecule Type
  • 6.2.2. By Nanoparticles Type
  • 6.2.3. By Application
  • 6.2.4. By Disease Indication
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Nanomedicine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Nanomolecule Type
      • 6.3.1.2.2. By Nanoparticles Type
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By Disease Indication
  • 6.3.2. Canada Nanomedicine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Nanomolecule Type
      • 6.3.2.2.2. By Nanoparticles Type
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By Disease Indication
  • 6.3.3. Mexico Nanomedicine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Nanomolecule Type
      • 6.3.3.2.2. By Nanoparticles Type
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By Disease Indication

7. Europe Nanomedicine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Nanomolecule Type
  • 7.2.2. By Nanoparticles Type
  • 7.2.3. By Application
  • 7.2.4. By Disease Indication
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Nanomedicine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Nanomolecule Type
      • 7.3.1.2.2. By Nanoparticles Type
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By Disease Indication
  • 7.3.2. France Nanomedicine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Nanomolecule Type
      • 7.3.2.2.2. By Nanoparticles Type
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By Disease Indication
  • 7.3.3. United Kingdom Nanomedicine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Nanomolecule Type
      • 7.3.3.2.2. By Nanoparticles Type
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By Disease Indication
  • 7.3.4. Italy Nanomedicine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Nanomolecule Type
      • 7.3.4.2.2. By Nanoparticles Type
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By Disease Indication
  • 7.3.5. Spain Nanomedicine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Nanomolecule Type
      • 7.3.5.2.2. By Nanoparticles Type
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By Disease Indication

8. Asia Pacific Nanomedicine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Nanomolecule Type
  • 8.2.2. By Nanoparticles Type
  • 8.2.3. By Application
  • 8.2.4. By Disease Indication
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Nanomedicine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Nanomolecule Type
      • 8.3.1.2.2. By Nanoparticles Type
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By Disease Indication
  • 8.3.2. India Nanomedicine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Nanomolecule Type
      • 8.3.2.2.2. By Nanoparticles Type
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By Disease Indication
  • 8.3.3. Japan Nanomedicine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Nanomolecule Type
      • 8.3.3.2.2. By Nanoparticles Type
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By Disease Indication
  • 8.3.4. South Korea Nanomedicine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Nanomolecule Type
      • 8.3.4.2.2. By Nanoparticles Type
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By Disease Indication
  • 8.3.5. Australia Nanomedicine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Nanomolecule Type
      • 8.3.5.2.2. By Nanoparticles Type
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By Disease Indication

9. Middle East & Africa Nanomedicine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Nanomolecule Type
  • 9.2.2. By Nanoparticles Type
  • 9.2.3. By Application
  • 9.2.4. By Disease Indication
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Nanomedicine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Nanomolecule Type
      • 9.3.1.2.2. By Nanoparticles Type
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By Disease Indication
  • 9.3.2. UAE Nanomedicine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Nanomolecule Type
      • 9.3.2.2.2. By Nanoparticles Type
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By Disease Indication
  • 9.3.3. South Africa Nanomedicine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Nanomolecule Type
      • 9.3.3.2.2. By Nanoparticles Type
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By Disease Indication

10. South America Nanomedicine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Nanomolecule Type
  • 10.2.2. By Nanoparticles Type
  • 10.2.3. By Application
  • 10.2.4. By Disease Indication
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Nanomedicine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Nanomolecule Type
      • 10.3.1.2.2. By Nanoparticles Type
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By Disease Indication
  • 10.3.2. Colombia Nanomedicine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Nanomolecule Type
      • 10.3.2.2.2. By Nanoparticles Type
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By Disease Indication
  • 10.3.3. Argentina Nanomedicine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Nanomolecule Type
      • 10.3.3.2.2. By Nanoparticles Type
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By Disease Indication

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Nanomedicine Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Johnson & Johnson Innovative Medicine
• 15.3. Sanofi S.A.
• 15.4. Amgen Inc.
• 15.5. Moderna, Inc.
• 15.6. Novo Nordisk A/S
• 15.7. Genentech, Inc.
• 15.8. Celgene Corporation
• 15.9. Vifor Pharma Group
• 15.10. Teva Pharmaceutical Industries Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer